Gemtuzumab Ozogamicin

From OncoWiki
Jump to: navigation, search

Indication

Acute Myeloid Leukemia

For the treatment of CD33+ AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy

Gemtuzumab 9mg/m2 IVI (2 hr) days 1 and 14 (and 21)

Up to three doses are given with at least 14 days, but no more than 28 days, between doses.

References

Leopold LH et. al Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol. 2003 Apr;1(4):220-5
Sievers EL et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 1;19(13):3244-5